Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial

AIMS: This two‐part, double‐blind, double‐dummy, randomized, placebo‐controlled trial (83 sites) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg and linagliptin (Lina) 5 mg fixed‐dose combinations (FDCs) in Japanese patients with type 2 diabetes mellitus (T2DM) who were poorly...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Kohei, Haneda, Masakazu, Tanaka, Yuko, Lee, Ganghyuck, Shiki, Kosuke, Miyamoto, Yuki, Solimando, Fernando, Lee, Jisoo, Lee, Christopher, George, Jyothis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585831/
https://www.ncbi.nlm.nih.gov/pubmed/30091172
http://dx.doi.org/10.1111/dom.13496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585831/
https://www.ncbi.nlm.nih.gov/pubmed/30091172
http://dx.doi.org/10.1111/dom.13496

Ejemplares similares